Moore Capital Management, LP Glaukos Corp Transaction History

Moore Capital Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$43.88 - $52.48 $3.71 Million - $4.43 Million	84,462 Added 157.87%	137,962 $6.91 Million
Q4 2022 Feb 14, 2023	SELL	$40.82 - $57.75 $2.74 Million - $3.87 Million	-67,024 Reduced 55.61%	53,500 $2.34 Million
Q3 2022 Nov 14, 2022	BUY	$46.84 - $58.49 $171,153 - $213,722	3,654 Added 3.13%	120,524 $6.42 Million
Q2 2022 Aug 15, 2022	SELL	$34.86 - $63.77 $3.32 Million - $6.07 Million	-95,189 Reduced 44.89%	116,870 $5.31 Million
Q1 2022 May 16, 2022	BUY	$44.33 - $57.82 $5.84 Million - $7.61 Million	131,642 Added 163.7%	212,059 $12.3 Million
Q4 2021 Feb 14, 2022	BUY	$40.27 - $56.99 $3.24 Million - $4.58 Million	80,417 New	80,417 $3.57 Million

341

46.8M

132K

188K

Ticker GKOS
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 47,596,900
Market Cap $7.18B
Description
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...

Get notified when there are updates to the investment portfolio of Moore Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Moore Capital Management, LP with notifications on news.